More recently, Wucherpfennig group published an elegant study where, by designing a powerful experimental set up, the authors temporally characterized the response of T-cell subsets to anti-PD-1 and anti-CTLA-4 treatments, both in the tumor and blood of head and neck cancer patients, in a neoadjuvant setting [103]. The gene discussed is CTLA4; the disease is neoplasm.